Clinical trial

Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）

NCT05429463

Study summary

ClinicalTrials.gov

Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

BIOLOGICAL · Unmapped registry intervention Sintilimab Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Carboplatin Normalized identity: carboplatin View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Albumin-Bound Paclitaxel Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2022-11-11

PhasePHASE3

Conditions

Squamous Cell Non-small Cell Lung Cancerunresolved

Interventions

SintilimabBIOLOGICAL

CarboplatinDRUG · verified · RxNorm: carboplatin

Albumin-Bound PaclitaxelDRUG

Sponsors & collaborators

Second Affiliated Hospital, Zhejiang University, School of Medicinelead sponsor

Mapped research locations

HangzhouZhejiang, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05429463 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.